Import from "@/components/mdx"

Low-Dose Testosterone in Women: How Your Genes Shape Your Response

Why the Same Dose Produces Wildly Different Results in Different Women

Standard compounded transdermal testosterone (typically 1% cream delivering approximately 300 mcg daily) produces measurable differences in serum-free testosterone even among women using the same tube from the same pharmacy. Two women can apply identical doses and end up with free testosterone levels that differ by a factor of three or more. The explanation sits partly in your genome.

Three gene systems do most of the pharmacogenomic work: the androgen receptor gene (AR) on the X chromosome, the sex hormone-binding globulin gene (SHBG), and the cytochrome P450 family of metabolizing enzymes, particularly CYP3A4 and CYP3A5. Variants in these genes change how much testosterone your skin absorbs, how much circulates as free (biologically active) hormone, and how sensitive your cells are to whatever testosterone reaches them.

The 2019 Global Consensus on Testosterone for Women acknowledged wide inter-individual variation in response and explicitly called for serum testosterone measurement before and during therapy to ensure levels stay within the physiological premenopausal range. The consensus did not, however, issue specific pharmacogenomic prescribing guidance because the female-specific trial data simply do not exist yet. That evidence gap is real and worth naming.

The framework below synthesizes what is known from male trials, female observational data, and mechanistic pharmacology into a practical clinical map for understanding why your response to low-dose testosterone may differ from another woman's.

The Androgen Receptor Gene: Where Sensitivity Lives

What the AR gene does

The androgen receptor (AR) gene encodes the intracellular protein that binds testosterone and dihydrotestosterone (DHT) and then translocates to the nucleus to alter gene transcription. Without a functional AR, testosterone in circulation does nothing. Variation in AR sensitivity is therefore just as clinically relevant as variation in circulating testosterone levels.

The CAG repeat polymorphism and its effects in women

The most studied AR variant is the CAG trinucleotide repeat in exon 1. This repeat region codes for a polyglutamine stretch in the AR N-terminal domain. Shorter repeats (roughly 9 to 20 CAG units) are associated with greater transcriptional activity, meaning the receptor responds more vigorously to a given testosterone concentration. Longer repeats (above 23 units) dampen that signal.

In men, the CAG repeat length has been correlated with libido, bone density response to testosterone, and prostate cancer risk. Female-specific data are thinner, but a 2003 study published in the Journal of Clinical Endocrinology and Metabolism found that AR CAG repeat length in women correlated with androgen-related phenotypes including sexual function scores and androgenic hair distribution, providing mechanistic plausibility that the same gene influences clinical outcomes in your sex.

A 2010 analysis in the European Journal of Endocrinology found that postmenopausal women with shorter AR CAG repeats reported higher sexual desire scores independent of circulating testosterone levels. That finding matters clinically: a woman with a short-repeat AR genotype may respond to a lower testosterone dose than the consensus target, while a woman with long-repeat AR may need levels closer to the upper end of the physiological premenopausal range to notice any benefit.

The GGN repeat: a secondary AR modifier

A second polymorphic site, the GGN repeat in exon 1, modulates AR mRNA stability rather than transcriptional potency. Longer GGN repeats reduce receptor protein abundance. One 2009 study in Human Reproduction found that GGN repeat length in women correlated with circulating androgen levels and menstrual cycle characteristics, suggesting this variant has real downstream effects on androgen biology in premenopausal women. Its effect in postmenopausal women on testosterone therapy has not been directly studied.

Practical clinical implication

If you are using compounded transdermal testosterone and experiencing no improvement in desire despite total testosterone levels in the premenopausal range (roughly 15 to 70 ng/dL free testosterone by equilibrium dialysis), a long AR CAG repeat genotype is a plausible biological explanation. Conversely, if you develop androgenic side effects (acne, clitoral sensitivity changes, mild hirsutism) at doses that keep serum levels within range, a short-repeat AR may be amplifying the signal.

SHBG: The Gatekeeper Gene That Controls How Much Testosterone Reaches Your Cells

How SHBG limits bioavailable testosterone

Sex hormone-binding globulin, produced in the liver, binds testosterone with high affinity. Only free testosterone (approximately 1 to 3% of total) and albumin-bound testosterone (loosely bound, considered bioavailable) enter cells and activate the AR. Women have higher SHBG concentrations than men on average, meaning a greater fraction of total testosterone is biologically inactive in female physiology at baseline.

Oral estrogen raises SHBG substantially. A postmenopausal woman taking oral estradiol alongside compounded transdermal testosterone may have SHBG levels 2 to 4 times higher than a woman using transdermal estradiol, significantly reducing free testosterone bioavailability from the same testosterone dose. This hormone-drug interaction is well documented and is one reason the 2019 Global Consensus recommends measuring free testosterone, not just total testosterone, during therapy.

SHBG gene variants and dose requirements

The SHBG gene on chromosome 17p13.1 carries a D327N polymorphism (rs6259) that reduces SHBG's binding affinity for testosterone, and a pentanucleotide TAAAA repeat in the promoter region that influences transcription. Women carrying the low-SHBG variant alleles tend to have lower circulating SHBG concentrations and therefore higher free testosterone for any given total testosterone level. Women with high-SHBG genotypes face the opposite: their liver produces more SHBG, their free fraction is smaller, and they may need a higher compounded dose or a switch away from oral estrogen to get the same clinical effect.

A 2020 review in the Journal of Clinical Endocrinology and Metabolism confirmed that SHBG concentrations in postmenopausal women are strongly heritable (heritability estimates of 40 to 60%), underscoring that SHBG level is not just a response to lifestyle but is substantially genetically determined.

CYP Enzyme Pharmacogenomics: Metabolism and Local Tissue Conversion

CYP3A4 and CYP3A5 in testosterone clearance

Testosterone is metabolized in the liver and gut wall primarily by CYP3A4, with CYP3A5 contributing particularly in women who carry the CYP3A5*1 allele (approximately 20% of European-ancestry women, and 40 to 80% of women of African ancestry). CYP3A5 expressers clear testosterone more rapidly. This is directly relevant to transdermal dosing: if your CYP3A5 genotype drives faster hepatic and intestinal testosterone catabolism, you may need a slightly higher dose to maintain equivalent bioavailable levels.

CYP3A4 itself shows important sex differences. Women have approximately 20 to 30% higher CYP3A4 activity than men on average, a difference confirmed in pharmacokinetic studies reviewed by the FDA's Drug Interaction Guidance resources. This means baseline testosterone clearance through CYP3A4 is inherently faster in female physiology, which is one pharmacokinetic argument for why the female physiological dose of testosterone is a fraction of the male dose rather than simply a weight-adjusted reduction.

CYP19A1 (aromatase) and local estrogen conversion

CYP19A1, the aromatase enzyme, converts testosterone to estradiol. In adipose tissue, this conversion is physiologically meaningful. Postmenopausal women with higher body mass index have more adipose aromatase activity, meaning a greater fraction of administered testosterone is converted locally to estrogen rather than remaining as active androgen. CYP19A1 variants (notably rs727479 in intron 4 and the TTTA repeat polymorphism) alter aromatase expression and have been associated in published data in Breast Cancer Research with differences in circulating estrogen levels in postmenopausal women. For women on low-dose testosterone, high-aromatase genotypes may experience more estrogen-mediated effects (breast tenderness, endometrial stimulation risk) alongside less androgenic benefit.

SRD5A (5-alpha reductase) and DHT conversion

5-alpha reductase, encoded by SRD5A1 and SRD5A2, converts testosterone to the more potent androgen dihydrotestosterone (DHT) in skin and genital tissue. This conversion is what drives androgenic side effects in skin (acne, oiliness, follicular sensitivity) and clitoral sensitivity. Women with higher SRD5A2 activity (associated with the V89L polymorphism) convert more transdermal testosterone to DHT locally at the application site, which may explain why some women develop localized androgenic side effects even at doses that keep serum testosterone in range.

Pharmacokinetics Specific to Transdermal Delivery in Women

Skin absorption variability

Transdermal absorption of testosterone in women is highly variable. The skin's permeability depends on site of application, skin hydration, and melanocyte-stimulating factors partly influenced by genetics. A 2016 pharmacokinetic study in Menopause found coefficient of variation for steady-state free testosterone exceeding 60% among postmenopausal women using the same transdermal formulation. This variability dwarfs what would be seen with oral or injectable delivery, making compounded transdermal dosing inherently less predictable.

Female-specific dosing targets

The physiological premenopausal total testosterone range in women is approximately 15 to 70 ng/dL depending on the assay and phase of the menstrual cycle. The 2019 Global Consensus recommends targeting the premenopausal physiological range (not exceeding the upper limit of this range) using a validated assay such as liquid chromatography-tandem mass spectrometry (LC-MS/MS). Immunoassays are insufficient at low female concentrations. This means not every lab test your clinician orders is accurate enough to guide dosing.

Pregnancy, Lactation, and Contraception: Required Reading

Testosterone is contraindicated in pregnancy. Exogenous androgens cause virilization of female fetuses, a well-documented teratogenic effect. The FDA's prescribing information for testosterone products assigns testosterone Pregnancy Category X status. Any woman of reproductive potential using compounded transdermal testosterone must use highly effective contraception. This is not optional and should be discussed before the first prescription is written.

Perimenopausal women are particularly at risk for unplanned pregnancy given irregular cycles and inconsistent ovulation, even when periods are becoming less frequent. Do not assume that cycle irregularity means infertility.

Lactation: Testosterone transfers into breast milk. The extent of infant exposure from maternal transdermal use is not well-studied in rigorous pharmacokinetic trials. Given the potential for androgen exposure to a nursing infant, the conservative clinical recommendation is to avoid testosterone therapy while breastfeeding. If testosterone is deemed necessary, the lowest effective dose and a non-breast site of application reduce (but do not eliminate) theoretical infant exposure.

Contraception interaction note: Progesterone-only IUDs (levonorgestrel-releasing) and copper IUDs do not raise SHBG and therefore do not reduce free testosterone bioavailability. Combined oral contraceptives raise SHBG substantially and would lower the free fraction of any co-administered testosterone. If you are using testosterone off-label for HSDD and also need contraception, a non-estrogen-containing method preserves the pharmacological effect of your testosterone dose.

Who This Therapy Is, and Is Not, Right For: A Life-Stage Map

Postmenopausal women (natural or surgical)

This is the population with the best evidence. The 2019 Global Consensus found that testosterone therapy produced a statistically significant and clinically meaningful improvement in sexual desire, arousal, pleasure, and orgasm in postmenopausal women with HSDD, with a standardized mean difference in sexual function scores of approximately 0.5 compared to placebo across randomized trials. Women with surgical menopause (bilateral oophorectomy) experience a more abrupt androgen drop and may notice larger symptomatic benefit.

Perimenopausal women

Evidence is extrapolated, not direct. The hormonal milieu is fluctuating, ovarian testosterone production is still partial, and SHBG dynamics are shifting. Prescribing is off-label on top of off-label. Clinicians who prescribe in this population rely on symptom assessment and free testosterone levels, not trial data specific to this stage.

Premenopausal women with HSDD or PCOS-related androgen excess

Testosterone supplementation is not established for premenopausal HSDD. Women with PCOS typically have elevated androgens and do not benefit from additional testosterone. Premenopausal women with low testosterone (documented on LC-MS/MS) and HSDD may be candidates in the hands of a reproductive endocrinologist, but this represents a significant evidence gap, and compounded testosterone in this group carries higher regulatory and safety uncertainty.

Women with conditions that affect androgen metabolism

Women with liver disease (reduced SHBG synthesis, altered CYP activity), thyroid disease (hypothyroidism raises SHBG), insulin resistance (lowers SHBG), or on drugs that inhibit or induce CYP3A4 (fluconazole, rifampicin, many anticonvulsants) will have altered testosterone pharmacokinetics. Dosing in these groups requires more frequent monitoring.

Monitoring: What to Measure and When

After beginning compounded transdermal testosterone at the standard dose of approximately 300 mcg per day, the 2019 Global Consensus recommends:

• Measure total testosterone and free testosterone (by LC-MS/MS) at 6 weeks to assess absorption and bioavailability.
• If levels are above the upper limit of the premenopausal physiological range, reduce the dose or stop therapy before side effects develop.
• Recheck at 6 months, then annually if stable.
• Assess sexual function symptom scores (using a validated tool such as the Female Sexual Function Index) at each interval to separate pharmacological from psychological drivers of response.

Women with genetic variants that drive higher DHT conversion (SRD5A2) or higher CYP3A5-mediated clearance may need more frequent early monitoring because their serum-free testosterone may behave less predictably at initiation.

The Evidence Gap: What We Do Not Know Yet

Women have been systematically excluded from pharmacogenomic trials of androgens. Nearly all AR CAG repeat, CYP3A4, and SRD5A2 pharmacogenomics research comes from men being treated for hypogonadism, prostate cancer, or male pattern baldness. The 2019 Global Consensus explicitly called for dedicated trials in women, including trials that account for menopausal status, concurrent hormone therapy, and route of administration. As of this writing, no large-scale pharmacogenomic trial in women on low-dose testosterone therapy has been published.

This means that every statement above about AR CAG repeats, SHBG genetics, CYP3A5, aromatase variants, and 5-alpha reductase in women is based on: (a) mechanistic extrapolation from male data, (b) small observational studies in women, or (c) physiological pharmacokinetic reasoning. The framework is scientifically grounded, but it is not yet evidence-based in the same way the core HSDD efficacy data are. Your clinician should know this distinction when you discuss genotype-guided dosing.

Side Effects Through a Pharmacogenomic Lens

The most commonly reported side effects of low-dose testosterone in women are androgenic: acne (in approximately 11% of women in pooled trial data), increased body or facial hair, and clitoral sensitivity changes. Scalp hair thinning occurs less frequently. Polycythemia, a concern in male dosing, is rare at female physiological doses but should be monitored in women with a baseline hematocrit above 45%.

Women with short AR CAG repeats and high SRD5A2 activity form a genotypic profile that may predict greater androgenic side-effect sensitivity at equivalent serum testosterone levels. This group may need lower-end dosing (150 to 200 mcg per day rather than 300 mcg) and application site rotation away from hairline areas. No clinical trial has prospectively validated this approach in women.

Compounding vs. Approved Products: A Regulatory Note

No testosterone product is currently FDA-approved for women in the United States. In Australia, Androfeme 1% cream (1 mg per gram, typically dosed at 0.5 mL delivering 5 mg) has regulatory approval for postmenopausal HSDD. Compounded testosterone in the U.S. Is prepared by 503A or 503B pharmacies under state pharmacy law, with no FDA manufacturing oversight. This means dose accuracy, sterility, and formulation consistency vary by compounder. Pharmacogenomic response variability is real even with pharmaceutical-grade products; with compounded preparations, formulation variability adds a second layer of inter-individual unpredictability that is separate from genetics.

Request a certificate of analysis from your compounding pharmacy confirming testosterone content and sterility testing. This is a reasonable quality-assurance step that any reputable compounder should provide on request.